KalVista appoints Benjamin Palleiko as CEO

KalVista announced that Benjamin Palleiko, the company’s current President, CBO and CFO, has been appointed as CEO and a director of the company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the company. This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the Konfident Phase 3 trial for its program sebetralstat as the first potential oral, on-demand therapy for hereditary angioedema, with a planned US NDA filing in the first half of this year. Ben Palleiko joined KalVista in 2016 as CFO. Prior to his business career, he served on active duty for seven years in the US Navy as a Naval Aviator flying carrier-based jet aircraft.